title: Short-term intravenous interferon therapy for chronic hepatitis B.
abstract: OBJECTIVE
  To investigate the therapeutic efficacy of short-term, multiple daily dosing of intravenous interferon (IFN) in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
  
  
  METHODS
  IFN-beta was intravenously administered at a total dose of 102 million international units (MIU) over a period of 28 d in 26 patients positive for HBeAg and HBV-DNA. IFN-beta was administered at doses of 2 MIU and 1 MIU on d 1, 3 MIU twice daily from d 2 to d 7, and 1 MIU thrice daily from d 8 to d 28. Patients were followed up for 24 wk after the end of treatment.
  
  
  RESULTS
  Six months after the end of the treatment, loss of HBV-DNA occurred in 13 (50.0%) of the 26 patients, loss of HBeAg in 9 (34.6%), development of anti-HBe in 10 (38.5%), HBeAg seroconversion in 8 (30.8%), and normalization of alanine aminotransferase (ALT) levels in 11 (42.0%).
  
  
  CONCLUSIONS
  This 4-wk long IFN-beta therapy, which was much shorter than conventional therapy lasting 12 wk or even more than 1 year, produced therapeutic effects similar to those achieved by IFN-alpha or pegylated-IFN-alpha (peg-IFN). Fewer adverse effects, greater efficacy, and a shorter treatment period led to an improvement in patients' quality of life. IFN-beta is administered intravenously, whereas IFN-alpha is administered intramuscularly or subcutaneously. Because both interferons are known to bind to an identical receptor and exert antiviral effects through intracellular signal transduction, the excellent results of IFN-beta found in this study may be attributed to the multiple doses allowed by the intravenous route.
authors.affiliation: Department of Internal Medicine, Himeji Red Cross Hospital, Hyogo 670-8540, Japan. hiroaki_okushin@hotmail.co.jp
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Okushin
authors.forename: Toru
authors.initials: T
authors.lastname: Ohnishi
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Morii
authors.forename: Koichi
authors.initials: K
authors.lastname: Uesaka
authors.forename: Shiro
authors.initials: S
authors.lastname: Yuasa
mesh_terms: D015088:2',5'-Oligoadenylate Synthetase / Q000097:blood; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004279:DNA, Viral / Q000097:blood; D004259:DNA-Directed DNA Polymerase / Q000097:blood; D004334:Drug Administration Schedule; D005260:Female; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000235:genetics / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007262:Infusions, Intravenous; D016899:Interferon-beta / Q000008:administration & dosage* / Q000009:adverse effects; D007564:Japan; D008297:Male; D010865:Pilot Projects; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D006513:Hepatitis B e Antigens; D016899:Interferon-beta; D004259:DNA-Directed DNA Polymerase; D015088:2',5'-Oligoadenylate Synthetase